focus -WSS

focus

author：explore 2025-09-30 09:08:23 Page View：6

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cigna, Humana reportedly in talks to merge
Next article： Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

explore

BioMarin wins approval for gene therapy to treat hemophilia A

AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

Despite FDA concern, risk that CAR

EngineeredreceptorsonthesurfaceofaT-lymphocytebindtoaleukemiacell.AdobeTheannouncementonTuesdaythatt

Guidelines to prevent youth baseball injuries need more muscle

Apitcheratthe2018LittleLeagueWorldSeries.RobCarr/GettyImages“Weallknowthatweareinthemiddleofanepidem

Despite FDA concern, risk that CAR

EngineeredreceptorsonthesurfaceofaT-lymphocytebindtoaleukemiacell.AdobeTheannouncementonTuesdaythatt

focus

knowledge

explore

Despite FDA concern, risk that CAR